A pharmaceutical company focused on treating aging and age-related diseases.

wefunder

An early-stage biotechnology company focused on aging research. The team has decades of experience in aging science and has collectively authored more than 200 papers. The company operates a platform that develops drug candidates intended to slow aging, reportedly achieving a 20% success rate in advancing candidates. Planned work includes testing the candidates in aging mice. The executive chairman previously served as chief executive officer of Sangamo Therapeutics, a biopharma company.

Simon Melov

Mark S Lucanic

Gordon Lithgow

Professor, Vice President Buck Institute

Gerostate Alpha (YC S18)

The update says the platform is validated and is delivering high-quality candidates to slow aging. It also states this is the last chance to join the round at the current valuation.

Final day before Gerostate Alpha closes

The company reports that more than 60 candidate compounds from its longevity and chemical/structural variant screens were tested in metabolic stability assays, and several passed and will be moved into aging mouse assays. Over the next 6–12 months, it plans to evaluate pre-clinical functional domains of aging including bone, muscle, metabolic, cardiovascular, and neurological outcomes.